Vivitrex (Alkermes/Cephalon).
Vivitrex, an injectable, sustained-release formulation of the opioid antagonist naltrexone, is being developed by Alkermes and Cephalon for the potential once-monthly treatment of alcoholism and opiate use disorder. Alkermes and Cephalon are currently awaiting Food and Drug Administration review of the Vivitrex new drug application, which was granted Priority Review in May 2005.
Heading
Christine E
CE
Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle-upon-Tyne NE3 3PW, UK. moore11@globalnet.co.uk
D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D009271:Naltrexone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D009292:Narcotic Antagonists; D009271:Naltrexone